PATENT CLAIM ANALYSIS

Application Number: 16060641
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "210210"]

Abstract:
The present invention relates to LpxC antibacterial compounds of Formula (IA): corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, compound preparation, treatment methods and uses for bacterial infections, especially those caused by gram-negative bacteria.

Claim (Index 13):
The compound of Formula (VI) according to  claim 12  which is: Ex. Compound Name Chemical Structure 53 (2R)-N-hydroxy-2-methanesulfonyl-4- [6-(4-methoxyphenyl)-1-oxo- 1,2-dihydroisoquinolin- 2-yl]-2-methylbutanamide   54 (2R)-N-hydroxy-2-methane- sulfonyl-2-methyl- 4-[6-(4-methylphenyl)-1-oxo-1,2- dihydroisoquinolin-2-yl]butanamide   55 (2R)-4-[6-(2-fluoro-4-methoxy- phenyl)-1-oxo-1,2-dihydro- isoquinolin-2-yl]-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   56 (2R)-N-hydroxy-2-methane- sulfonyl-2-methyl-4-(1-oxo-6-phenyl- 1,2-dihydroisoquinolin-2- yl)butanamide   57 (2R)-4-[6-(1,3-dihydro-2- benzofuran-5-yl)-1-oxo-1,2- dihydroisoquinolin-2-yl]-N-hydroxy-2- methanesulfonyl-2-methylbutanamide)   58 (2R)-N-hydroxy-2-methane- sulfonyl-2-methyl-4-[6-(5-methyl- 1,3-thiazol-2-yl)-1-oxo-1,2- dihydroisoquinolin-2-yl]butanamide   59 (2R)-4-[6-(4-cyano-2- fluorophenyl)-1-oxo-1,2- dihydroisoquinolin-2-yl]-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   60 (2R)-N-hydroxy-2-methanesulfonyl- 4-[6-(6-methoxypyridin-3-yl)-1-oxo-1,2- dihydroisoquinolin-2-yl]-2- methylbutanamide   61 (2R)-4-{6-[4-(dimethyl- amino)phenyl]-1-oxo-1,2-dihydro- isoquinolin-2-yl}-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   62 (2R)-4-{6-[6-(dimethyl- amino)pyridin-3-yl]-1-oxo-1,2-dihydro- isoquinolin-2-yl}-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   63 (2R)-4-{6-[2-(dimethyl- amino)pyrimidin-5-yl]-1-oxo-1,2- dihydroisoquinolin-2-yl}-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   64 (2R)-N-hydroxy-2-methanesulfonyl- 2-methyl-4-(6-{4-[(morpholin-4- yl)methyl]phenyl}-1-oxo- 1,2-dihydroisoquinolin-2-yl)butanamide   65 (2R)-4-(6-{4-[(dimethylamino)methyl]-2- fluorophenyl}-1-oxo- 1,2-dihydroisoquinolin-2- yl)-N-hydroxy-2-methanesulfonyl-2- methylbutanamide   66 (2R)-4-[6-(2-fluoro-4-{[(2- methoxyethyl)(methyl)amino]meth- yl}phenyl)-1-oxo-1,2-dihydroiso- quinolin-2-yl]-N-hydroxy- 2-methanesulfonyl-2-methylbutanamide (GSK3212160A)   67 (2R)-4-[6-(2-fluoro-4-{[(2-methoxy- ethyl)amino]methyl}phenyl)-1-oxo- 1,2-dihydroisoquinolin-2-yl]-N-hydroxy- 2-methanesulfonyl-2- methylbutanamide   68 (2R)-4-[6-(2-fluoro-4-{[(2-methoxy-2- methylpropyl)amino]meth- yl}phenyl)-1-oxo-1,2-dihydro- isoquinolin-2-yl]-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   69 (2R)-4-(6-{4-[(dimethylamino)methyl]- 2,3-difluorophenyl}-1-oxo- 1,2-dihydroisoquinolin- 2-yl)-N-hydroxy-2-methanesulfonyl-2- methylbutanamide   70 (2R)-4-[6-(2-fluoro-4-{[(3-methoxy- propyl)(methyl)amino]methyl}phenyl)- 1-oxo-1,2-dihydroiso- quinolin-2-yl]-N-hydroxy- 2-methanesulfonyl-2-methylbutanamide   71 (2R)-4-[6-(2,3-difluoro-4-{[(2- methoxyethyl)amino]meth- yl}phenyl)-1-oxo-1,2-dihydro- isoquinolin-2-yl]-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   72 (2R)-4-[6-(4-{[(2-ethoxy- ethyl)amino]methyl}-2- fluorophenyl)-1-oxo-1,2-dihydro- isoquinolin-2- yl]-N-hydroxy-2-methanesulfonyl-2- methylbutanamide   73 (2R)-4-{6-[2-fluoro-4-({[2-(propan-2- yloxy)ethyl]amino}meth- yl)phenyl]-1-oxo-1,2- dihydroisoquinolin-2-yl}-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   74 (2R)-4-[6-(2-fluoro-4-{[(2- hydoxyethyl)(meth- yl)amino]methyl}phenyl)-1- oxo-1,2-dihydroisoquinolin- 2-yl]-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   75 (2R)-4-(6-{4-[(cyclo- propylamino)methyl]phenyl}-1-oxo-1,2- dihydroisoquinolin-2-yl)-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   76 (2R)-4-(6-{4-[(cyclopropyl- amino)methyl]-2-fluorophenyl}-1-oxo- 1,2-dihydroisoquinolin-2- yl)-N-hydroxy-2-methanesulfonyl-2 methylbutanamide   77 (2R)-N-hydroxy-2-methane- sulfonyl-2-methyl-4-(1-oxo-6- {4-[(1,2,2-trimethylhydrazin-1- yl)methyl]phenyl}-1,2-dihydroiso- quinolin-2-yl)butanamide   78 (2R)-N-hydroxy-2-methane- sulfonyl-4-(6-{4-[(methoxy- amino)methyl]phenyl}-1-oxo-1,2- dihydroisoquinolin-2-yl)-2- methylbutanamide   79 (2R)-4-(6-{4-[(2,2-dimethylhydrazin-1- yl)methyl]phenyl}-1-oxo-1,2- dihydroisoquinolin-2-yl)-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   80 (2R)-N-hydroxy-2-methanesulfonyl- 2-methyl-4-(6-{4-[2-(morpholin- 4-yl)ethyl]phenyl}-1-oxo-1,2- dihydroisoquinolin-2-yl)butanamide   81 (2R)-N-hydroxy-2-methane- sulfonyl-2-methyl-4-(1-oxo- 6-{4-[(2-oxopyrrolidin-1- yl)methyl]phenyl}-1,2-dihydro- isoquinolin-2-yl)butanamide   82 (2R)-4-[6-(6-{2-[cyclopropyl(meth- yl)amino]ethoxy}pyridin-3- yl)-1-oxo-1,2-dihydroisoquinolin- 2-yl]-N-hydroxy-2-methanesulfonyl-2- methylbutanamide   83 (2R)-4-[4-fluoro-6-(4-methoxy- phenyl)-1-oxo-1,2-dihydro- isoquinolin-2-yl]-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   84 (2R)-4-(4-fluoro-1-oxo-6-phenyl-1,2- dihydroisoquinolin-2-yl)-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   85 (2R)-4-(6-{4-[(dimethyl- amino)methyl]phenyl}-4-fluoro- 1-oxo-1,2-dihydroisoquinolin-2-yl)-N- hydroxy-2-methanesulfonyl-2- methylbutanamide   86 (2R)-4-[6-(6-ethoxypyridin-3-yl)- 4-fluoro-1-oxo-1,2-dihydroiso- quinolin-2-yl]-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   87 (2R)-4-[4-fluoro-6-(6-methoxy- pyridin-3-yl)-1-oxo-1,2-dihydro- isoquinolin-2-yl]-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   88 (2R)-4-[4-fluoro-6-(2-fluoro-4-{[(2- methoxyethyl)amino]meth- yl}phenyl)-1-oxo-1,2-dihydro- isoquinolin-2-yl]-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   89 (2R)-4-(6-{4-[(dimethyl- amino)methyl]-2- fluorophenyl}-4-fluoro-1-oxo-1,2- dihydroisoquinolin-2-yl)-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   90 (2R)-4-{6-[6-(dimethyl- amino)pyridin-3-yl]-4-fluoro-1- oxo-1,2-dihydroisoquinolin-2-yl}-N- hydroxy-2-methanesulfonyl-2- methylbutanamide   93 (2R)-N-hydroxy-4-{6-[4-(2- hydroxyethyl)phenyl]-1-oxo-1,2- dihydroisoquinolin-2-yl}-2-methane- sulfonyl-2-methylbutanamide   94 2-(4-{2-[(3R)-3-(hydroxycarbamoyl)- 3-methanesulfonyl-3-methyl- propyl]-1-oxo-1,2- dihydroisoquinolin-6-yl}phenyl)ethyl  2-(dimethylamino)acetate a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 94.0
- Lexical Diversity: 1.10526
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14004105', '14068956', '14154239', '13515607', '14110165']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7825153918215645
- 35 USC 102 Novelty (BERT): 0.549689816830232
- Combined Prediction Score: 0.7592328343224313
- Mean Citation Score: 356.35282599999994
- Max Citation Score: 394.587
- Similarity Product: 297.8310540093184

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test